Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Chevron (CVX) vs Johnson & Johnson (JNJ): Weighing +50% YTD Momentum Against Defensive Stability

Chevron (CVX) vs Johnson & Johnson (JNJ): Weighing +50% YTD Momentum Against Defensive Stability

Key Takeaways

  • Chevron (CVX) and Johnson & Johnson (JNJ) sit in unrelated industries — energy versus healthcare — making this a contrast between cyclical commodity exposure and defensive diversification.
  • CVX has delivered notably stronger recent momentum, climbing near its 52-week high on record refining profits, while JNJ has risen more modestly and traded sideways-to-lower after its latest quarterly report.
  • JNJ offers a steadier, dividend-focused profile with a diversified pharmaceutical and medical-technology business, though slower MedTech growth and talc litigation have weighed on sentiment.
  • Tickeron AI Verdict: CVX is the ticker of choice in this comparison, favored for its stronger trend consistency and positive relative performance.
  • For deeper context, explore CVX Major News and CVX Today's Price Move, as well as JNJ Major News and JNJ Today's Price Move.
  • To see how automated strategies are positioning across the market, browse the Trending AI Robots page.

Setting the Stage for This Comparison

Comparing CVX and JNJ highlights two distinct investment profiles. Chevron Corporation, an integrated energy major, is driven by commodity prices, refining margins, and production growth, while Johnson & Johnson, a healthcare conglomerate, is anchored by pharmaceuticals and medical devices with historically defensive demand. Both are large-cap, dividend-paying blue chips, but their risk drivers and recent market positioning diverge sharply. This stock comparison is relevant for investors weighing cyclical upside against defensive stability, as well as traders evaluating relative performance and momentum in the current market environment.

Chevron's Recent Performance and Drivers

Chevron Corporation is one of the world's largest integrated energy companies, operating across upstream oil and gas production and downstream refining and chemicals. Recent weeks have been favorable for the stock, which has traded near its 52-week high and posted a roughly 50% year-to-date gain, outpacing several integrated-energy peers. The catalyst has been an unusually strong refining environment: global supply disruptions linked to conflicts in the Middle East and Ukraine have taken a meaningful share of worldwide refining capacity offline, lifting margins. Chevron's U.S. refineries ran at near 98% utilization and set a record for crude throughput, driving downstream earnings to roughly $4.9 billion in its most recent quarter — a record for the segment. I also checked this using Tickeron’s AI Trend Prediction Engine to see how the momentum stacks up.

Beyond refining, Chevron has expanded its long-duration portfolio through the prior Hess acquisition, which added stakes in Guyana's offshore fields, and through a planned multi-billion-dollar investment in Venezuela. The company has also maintained disciplined capital spending, reduced debt, and continued a decades-long streak of dividend growth. These factors, combined with upward earnings-per-share (EPS) estimate revisions, have supported positive sentiment.

Johnson & Johnson's Recent Performance and Drivers

Johnson & Johnson is a diversified healthcare company operating two main segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). Recent market activity has been more mixed for JNJ. The company reported solid top-line growth in its latest quarter, with sales rising roughly 6% and its pharmaceutical division growing about 8% on strength in drugs such as Darzalex and Tremfya. However, the stock retreated after the report, as slower MedTech growth, weakness in international markets, and a sizable one-time talc litigation charge weighed on investor sentiment. From what I see, a quick look at Tickeron’s AI Pattern Search Engine helped put the earnings reaction in context.

JNJ raised its full-year sales guidance and continues to benefit from a deep pipeline of new medicines, including oncology and immunology products that are helping offset the loss of exclusivity (LOE) on the blockbuster drug Stelara. Yet the company faces headwinds: patent expirations, pricing pressure, and the drag of its lower-growth medical-device business. Its profile remains defensive, with a long dividend record and lower beta (a measure of sensitivity to broader market swings) than most cyclical stocks.

Automated Trading Strategies in Focus

Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies. Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, but only the strongest performers best suited to current market conditions earn a place in this featured section. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the set of tickers they follow — ranging from momentum and swing strategies to longer-horizon approaches. By filtering for the most relevant robots, the page helps traders identify automated tools aligned with today's market environment. Explore the Trending AI Robots page to review the current lineup.

Head-to-Head Comparison

The two companies differ fundamentally in business model and risk profile. CVX is a cyclical energy producer whose earnings hinge on oil and gas prices and refining spreads; its growth drivers are production expansion, capital discipline, and supply-constrained commodity markets. JNJ, by contrast, generates steadier demand from healthcare spending and relies on drug launches and pipeline execution to offset patent expiries. One thing that stands out is how CVX adds energy-beta and inflation-commodity sensitivity, while JNJ offers defensive healthcare positioning with lower volatility but slower headline growth.

In terms of recent momentum, CVX has the clear edge, having rallied strongly and sustained an upward trend near record levels. JNJ's trajectory has been choppier, with solid fundamentals but negative near-term price reactions to its latest earnings and guidance. Risk factors contrast as well. CVX faces commodity-price swings and the potential normalization of elevated refining margins. JNJ faces litigation uncertainty, drug-pricing regulation, and a patent cliff. From a valuation standpoint, JNJ trades at a higher price-to-earnings (P/E) multiple, reflecting its steadier cash flows, while CVX's lower multiple reflects cyclical earnings that may not fully repeat.

Tickeron AI Verdict

Based on observable factors, Tickeron's AI would currently favor CVX in this comparison. The stock demonstrates stronger trend consistency, sustained relative performance versus peers, and positive earnings-momentum signals, alongside a robust cash-flow and balance-sheet position. JNJ remains a high-quality defensive compounder, but its mixed MedTech growth, litigation overhang, and recent price softness suggest comparatively weaker near-term positioning. This is a probabilistic assessment of momentum and market positioning rather than a definitive forecast, and it reflects the balance of current technical and fundamental signals rather than a judgment on long-term business quality.

Integrating Tickeron AI Tools Into My Process

I often turn to Tickeron’s AI Trading Bots when evaluating how automated strategies are aligning with stocks like these. The platform lets me review performance across different market conditions and timeframes, which adds useful perspective to the manual analysis without replacing it. It has become a regular part of checking relative strength and trend signals before forming a final view.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CVX, JNJ

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


CVX in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 04, 2026

CVX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 21 of 29 cases where CVX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 72%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 35 of 53 cases where CVX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 66%.

CVX moved above its 50-day moving average on November 12, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +3.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVX advanced for three days, in 230 of 376 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.

The Aroon Indicator entered an Uptrend today. In 190 of 341 cases where CVX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.

Bearish Trend Analysis

The 10-day RSI Indicator for CVX moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 23 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 53%.

The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CVX as a result. In 39 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 45%.

The Moving Average Convergence Divergence Histogram (MACD) for CVX turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 27 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 51%.

The 10-day moving average for CVX crossed bearishly below the 50-day moving average on November 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 44%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 40%.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 31, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. CVX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 63 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.196) is normal, around the industry mean (1.508). CVX has a moderately high P/E Ratio (20.404) as compared to the industry average of (10.200). Projected Growth (PEG Ratio) (0.903) is also within normal values, averaging (1.088). Dividend Yield (0.033) settles around the average of (0.053) among similar stocks. P/S Ratio (2.004) is also within normal values, averaging (3.764).

Notable companies

The most notable companies in this group are ExxonMobil Holdings Corporation (NYSE:XOM), Chevron Corp (NYSE:CVX), Petroleo Brasileiro Sa-Petrobras ADS (REP 1 Common Share) (NYSE:PBR), BP plc (NYSE:BP), Suncor Energy (NYSE:SU), YPF Sociedad Anonima (NYSE:YPF).

Industry description

Integrated oil companies are involved across nearly the entire oil value chain – from upstream operations like exploration and production, to downstream functions of refining and marketing. Exxon Mobil Corporation, Chevron Corporation and BP are major integrated oil companies. Their bottom lines’ response to crude oil prices could depend on the proportion of upstream vs. downstream businesses; for example, if a company has substantial downstream business, the adverse impact on their upstream business due to falling crude prices could be mitigated by benefits to its downstream business.

Market Cap

The average market capitalization across the Integrated Oil Industry is 124.37B. The market cap for tickers in the group ranges from 63.2K to 682.04B. XOM holds the highest valuation in this group at 682.04B. The lowest valued company is CRRDF at 63.2K.

High and low price notable news

The average weekly price growth across all stocks in the Integrated Oil Industry was -2%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -5%. SLNG experienced the highest price growth at 8%, while SKYQ experienced the biggest fall at -42%.

Volume

The average weekly volume growth across all stocks in the Integrated Oil Industry was -30%. For the same stocks of the Industry, the average monthly volume growth was -27% and the average quarterly volume growth was -32%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 75
Price Growth Rating: 55
SMR Rating: 56
Profit Risk Rating: 30
Seasonality Score: -40 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which explores and refines oil and natural gas

Industry IntegratedOil

Industry
Integrated Oil
Address
1400 Smith Street
Phone
+1 832 854-1000
Employees
43039
Web
https://www.chevron.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.